[Screening for asymptomatic Chlamydia trachomatis infection: cost-effectiveness favorable at a minimum prevalence rate of 3% or more].
P C
PC
Habets
D000328:Adult; D002690:Chlamydia Infections / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control* / Q000652:urine; D002692:Chlamydia trachomatis / Q000302:isolation & purification*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000191:economics; D009426:Netherlands / Q000453:epidemiology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000191:economics* / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control* / Q000652:urine; D015995:Prevalence